4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MaaT Pharma SA (MAAT) operates in the Biotechnology industry and is headquartered in Lyon, France with about 52 employees. Its market capitalization is roughly €54 million. In the fiscal year ended 2025-12-31, MAAT reported €4M in revenue and (€31M) in net income.
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | €4M | €3M | €2M | €1M |
| Gross Profit | €3M | €2M | €2M | €1M |
| Operating Income (EBIT) | (€30M) | (€28M) | (€20M) | (€14M) |
| Net Income | (€31M) | (€29M) | (€20M) | (€14M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €45M | €38M | €43M | €45M | — |
| Total Liabilities | €43M | €28M | €22M | €18M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MAAT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms